GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,831.50p
   
  • Change Today:
    -92.00p
  • 52 Week High: 2,208.00
  • 52 Week Low: 1,644.00
  • Currency: UK Pounds
  • Shares Issued: 4,045.43m
  • Volume: 16,828,085
  • Market Cap: £74,092m
  • RiskGrade: 129
  • Beta: 0.00

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Luke Miels
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Anne Beal
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Vishal Sikka
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Hal Barron , Wendy Becker , Jeannie Lee , Gavin Screaton, Roy Jakobs

Contact Details

Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com/en-gb/

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARK, FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,831.50p
Change Today -92.00p
% Change -4.78 %
52 Week High 2,208.00
52 Week Low 1,644.00
Volume 16,828,085
Shares Issued 4,045.43m
Market Cap £74,092m
Beta 0.00
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
77.11% below the market average77.11% below the market average77.11% below the market average77.11% below the market average77.11% below the market average
2.44% above the sector average2.44% above the sector average2.44% above the sector average2.44% above the sector average2.44% above the sector average
Price Trend
75.21% above the market average75.21% above the market average75.21% above the market average75.21% above the market average75.21% above the market average
67.44% above the sector average67.44% above the sector average67.44% above the sector average67.44% above the sector average67.44% above the sector average
Income
20.06% above the market average20.06% above the market average20.06% above the market average20.06% above the market average20.06% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Growth
40.79% above the market average40.79% above the market average40.79% above the market average40.79% above the market average40.79% above the market average
57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 12
Sell 2
Strong Sell 0
Total 21
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 12-Nov-26 13-Aug-26
Paid 07-Jan-27 08-Oct-26
Amount 17.00p 17.00p

Trades for 28-Oct-2026

Time Volume / Share Price
17:05 3,852,212 @ 1,879.50p
17:05 3,852,212 @ 1,879.50p
16:48 2,634 @ 1,831.50p
16:38 1,478 @ 1,831.50p
16:38 4,348 @ 1,831.50p

GSK Key Personnel

CEO Luke Miels

Top of Page